BlackRock Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

BlackRock Group’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$298K	Buy	9,313 +1,339	+17%	+$57.1K	﹤0.01%	2541
2016 Q3	$399K	Buy	7,974 +2,448	+44%	+$102K	﹤0.01%	2385
2016 Q2	$234K	Sell	5,526 -67	-1%	-$3.65K	﹤0.01%	2524
2016 Q1	$369K	Buy	5,593 +1,721	+44%	+$89.8K	﹤0.01%	2356
2015 Q4	$240K	Sell	3,872 -1,896	-33%	-$133K	﹤0.01%	2467
2015 Q3	$386K	Buy	5,768 +2,571	+80%	+$210K	﹤0.01%	2298
2015 Q2	$311K	Sell	3,197 -1,959	-38%	-$186K	﹤0.01%	2445
2015 Q1	$482K	Sell	5,156 -1,913	-27%	-$163K	﹤0.01%	2215
2014 Q4	$629K	Buy	7,069 +6,439	+1,022%	+$469K	﹤0.01%	2144
2014 Q3	$44K	Hold	630	–	–	﹤0.01%	2701
2014 Q2	$37K	Buy	630 +550	+688%	+$27.9K	﹤0.01%	2729
2014 Q1	$3K	Sell	80 -560	-88%	-$24K	﹤0.01%	2739
2013 Q4	$27K	Hold	640	–	–	﹤0.01%	2597
2013 Q3	$19K	Hold	640	–	–	﹤0.01%	2806
2013 Q2	$34K	Buy	+640	New	+$28.1K	﹤0.01%	2495

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's MACK Position: Q4 2016 in Review

BlackRock Group increased its Merrimack Pharmaceuticals, Inc. (MACK) stake by 17% in Q4 2016, buying an estimated $57.1K and bringing the position to 9,313 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #2541.

BlackRock Group first reported a position in MACK in Q2 2013 and has held it in 15 quarters since. The position peaked at $629K in Q4 2014. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

BlackRock Group held 9,313 shares of Merrimack Pharmaceuticals, Inc. worth $298K as of Q4 2016.
BlackRock Group bought 1,339 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $57.1K.
Merrimack Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2541 holding.
BlackRock Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Group's Merrimack Pharmaceuticals, Inc. position peaked at $629K in Q4 2014.
136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.